Stock A330350 WITHUS PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials WITHUS PHARMACEUTICAL Co.,LTD.

Equities

A330350

KR7330350000

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-06-11 pm EDT 		5-day change 1st Jan Change
7,820 KRW +0.64% Intraday chart for WITHUS PHARMACEUTICAL Co.,LTD. -0.89% -19.63%
2023 WITHUS PHARMACEUTICAL Co.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2020 Withuspharmaceutical Co.,Ltd. has completed an IPO in the amount of KRW 25.44 billion. CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 189,477 138,481 123,616 128,366
Enterprise Value (EV) 1 167,261 119,107 118,527 137,174
P/E ratio 17.9 x 32.5 x 49.8 x 16.1 x
Yield - - - -
Capitalization / Revenue 3.55 x 2.41 x 1.91 x 1.6 x
EV / Revenue 3.13 x 2.07 x 1.83 x 1.71 x
EV / EBITDA 18.2 x 18.6 x 17.4 x 12.8 x
EV / FCF 107 x -39.6 x -10.8 x -10.1 x
FCF Yield 0.93% -2.53% -9.23% -9.9%
Price to Book 2.46 x 1.71 x 1.49 x 1.42 x
Nbr of stocks (in thousands) 13,189 13,189 13,193 13,193
Reference price 2 14,367 10,500 9,370 9,730
Announcement Date 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 50,945 51,732 53,406 57,419 64,680 80,119
EBITDA 1 11,776 11,963 9,207 6,387 6,826 10,754
EBIT 1 11,176 10,935 7,230 4,886 4,878 7,909
Operating Margin 21.94% 21.14% 13.54% 8.51% 7.54% 9.87%
Earnings before Tax (EBT) 1 11,076 11,023 7,761 5,240 4,158 9,141
Net income 1 8,491 8,661 6,652 4,264 2,479 7,959
Net margin 16.67% 16.74% 12.46% 7.43% 3.83% 9.93%
EPS 2 27,390 27,940 804.0 323.3 188.0 603.4
Free Cash Flow 1 3,713 10,794 1,562 -3,011 -10,942 -13,576
FCF margin 7.29% 20.86% 2.93% -5.24% -16.92% -16.95%
FCF Conversion (EBITDA) 31.53% 90.23% 16.97% - - -
FCF Conversion (Net income) 43.73% 124.62% 23.48% - - -
Dividend per Share - - - - - -
Announcement Date 8/29/18 8/29/19 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - 8,809
Net Cash position 1 9,000 17,398 22,216 19,373 5,089 -
Leverage (Debt/EBITDA) - - - - - 0.8191 x
Free Cash Flow 1 3,713 10,794 1,562 -3,011 -10,942 -13,576
ROE (net income / shareholders' equity) 21.4% 17.9% 12.4% 5.4% 3.02% 9.18%
ROA (Net income/ Total Assets) 10.5% 9.41% 6.64% 2.71% 2.56% 3.95%
Assets 1 81,009 92,077 100,200 157,191 96,926 201,401
Book Value Per Share 2 142,245 169,124 5,829 6,136 6,295 6,839
Cash Flow per Share 2 21,467 17,989 1,175 1,049 683.0 695.0
Capex 1 1,590 1,962 5,264 6,667 15,332 10,807
Capex / Sales 3.12% 3.79% 9.86% 11.61% 23.7% 13.49%
Announcement Date 8/29/18 8/29/19 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
WITHUS PHARMACEUTICAL CO.,LTD. Stock WITHUS PHARMACEUTICAL Co.,LTD.
-19.63% 75.62M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+48.79% 781B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.90% 639B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.43% 330B
ABBVIE INC. Stock AbbVie Inc.
+7.18% 293B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.43% 248B
ROCHE HOLDING AG Stock Roche Holding AG
+0.12% 221B
NOVARTIS AG Stock Novartis AG
+11.62% 217B
AMGEN INC. Stock Amgen Inc.
+4.53% 162B
PFIZER, INC. Stock Pfizer, Inc.
-3.92% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A330350 Stock
  4. Financials WITHUS PHARMACEUTICAL Co.,LTD.